Cypre Inc. is a biotechnology company developing novel 3D in vitro models of the tumor microenvironment (TME) for cancer drug discovery.
Cypre has raised $875K in total funding. The most recent round was Convertible Note. The last funding was announced in October 2022.
Cypre is headquartered in San Francisco, United States.
Cypre Inc. is a biotechnology company developing novel 3D in vitro models of the tumor microenvironment (TME) for cancer drug discovery.
Cypre is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cypre — Funding & Investors." VCBacked, October 22, 2022, https://www.vcbacked.co/company/cypre. Accessed October 3, 2026.
VCBacked. (2022). Cypre — Funding & Investors. Retrieved October 3, 2026, from https://www.vcbacked.co/company/cypre
{{cite web |title=Cypre — Funding & Investors |url=https://www.vcbacked.co/company/cypre |website=VCBacked |access-date=October 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated